N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?

Gregory W. Albers, Mark P. Goldberg, Dennis W. Choi

Research output: Contribution to journalReview articlepeer-review

235 Scopus citations


Antagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well‐developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

Original languageEnglish (US)
Pages (from-to)398-403
Number of pages6
JournalAnnals of neurology
Issue number4
StatePublished - Apr 1989
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?'. Together they form a unique fingerprint.

Cite this